Tirzepatide
DUAL-HFrEF
Eli Lilly · Phase 3 · Not yet recruiting · Enrollment 60
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide: endpoint not reported
- Placebo: endpoint not reported